{
    "2019-04-02": [
        [
            {
                "time": "",
                "original_text": "恒瑞、华润、九州通等药企市值排行出炉",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "华润",
                        "九州通",
                        "药企",
                        "市值"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "凭借政策红利 江河集团加速医疗转型进程",
                "features": {
                    "keywords": [
                        "政策红利",
                        "江河集团",
                        "医疗转型"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【晨会聚焦】4月资产配置观：一波三折，去伪存真",
                "features": {
                    "keywords": [
                        "资产配置",
                        "4月",
                        "一波三折",
                        "去伪存真"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-01",
                "original_text": "【医药】江琦、祝嘉琦（研究助理）：2019年4月月报-医药创新是大方向，关注Q1高增长的优质公司-20190401",
                "features": {
                    "keywords": [
                        "医药创新",
                        "优质公司",
                        "Q1高增长",
                        "2019年4月"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}